On April 11, 2023 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, will present new data showcasing the performance of its methylation platform to detect cancer across the early- and post-diagnosis settings at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Orlando, April 14-19, 2023 (Press release, Grail, APR 11, 2023, View Source [SID1234629973]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Data at AACR (Free AACR Whitepaper) from our clinical development program support the potential of our methylation-based technology platform to transform cancer detection and care for people across all stages of their cancer journey," said Josh Ofman, MD, MSHS, president at GRAIL. "In addition to case studies of our GalleriⓇ multi-cancer early detection test in clinical practice, and demonstrating the unmet need for patients presenting with non-specific symptoms suggestive of cancer, we are excited to share results evaluating the performance of our new research-use only, methylation-based solution for post-diagnosis applications."

In the early-diagnosis setting, GRAIL will present real-world case studies of the Galleri multi-cancer early detection (MCED) test that demonstrate how Galleri led to early detection and treatment of cancer in asymptomatic individuals and directed diagnostic evaluation. In these instances, the Galleri test allowed the cancers to be detected in early stages and before clinical presentation.

In the post-diagnosis setting, analytical validation data will show how GRAIL’s targeted methylation technology platform can be used for diagnostic decision support to aid in achieving timely and cost-effective management of patients and after cancer diagnosis. GRAIL will present results from an analytical validation of its research-use only technology solution to accelerate cancer research in the post-diagnosis setting, launched as an offering to biopharmaceutical companies in January 2023. Potential research use cases for the methylation-based solution include, but are not limited to, prognosis, minimal residual disease detection, and recurrence monitoring across different cancer types.

Late-Breaking Poster Sessions

Title: Analytical validation of a tissue-free, multi-cancer, post-diagnosis cancer research test that uses cell-free DNA methylation profiling
Abstract Number: LB297
Session Title: Late-Breaking Research: Clinical Research 3
Date/Time: Wednesday, April 19, 2023, 9 AM – 12:30 PM EST
Location: Section 34

Poster Sessions

Title: A case of stage I HPV-mediated oropharyngeal squamous cell carcinoma (SCC) diagnosed using a multi-cancer early detection (MCED) test
Abstract Number: 6523
Session Title: Early Detection and Molecular Markers of Prevention
Date/Time: Wednesday, April 19, 2023, 9 AM – 12:30 PM EST
Location: Section 28

Title: A case of stage IIA anal squamous cell carcinoma (SCC) diagnosed using a multi-cancer early detection (MCED) test
Abstract Number: 6503
Session Title: Early Detection and Molecular Markers of Prevention
Date/Time: Wednesday, April 19, 2023, 9 AM – 12:30 PM EST
Location: Section 28

Title: Clonal B-cell expansion and the potential challenges to blood-based early cancer detection
Abstract Number: 779
Session Title: Omics and Imaging Approaches in Cancer Risk, Early Detection and Response Assessment
Date/Time: Sunday, April 16, 2023, 1:30 PM – 5 PM EST
Location: Section 28

Title: Patient characteristics, diagnostic journey, and cancer enrichment among pts with nonspecific signs and/or symptoms in the US community oncology setting: a real-world retrospective study
Abstract Number: 6752
Session Title: Retrospective Clinical Analyses 2
Date/Time: Wednesday, April 19, 2023, 9 AM – 12:30 PM EST
Location: Section 42

Title: Utility of ctDNA-based targeted methylation MRD assay for hematological malignancies
Session Title: Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3
Date/Time: Monday, April 17, 2023, 1:30 PM – 5 PM EST
Location: Section 43
Abstract Number: 3369